LRP10 is a low-density lipoprotein receptor-related protein implicated in neurodegeneration and immune regulation. In the brain, LRP10 is primarily expressed in non-neuronal cells including astrocytes and neurovasculature, with undetectable levels in neurons under normal conditions 1. LRP10 localizes to the trans-Golgi network, plasma membrane, retromer, and early endosomes, where it interacts with SORL1 in intracellular vesicle trafficking pathways 1. Mechanistically, LRP10 is secreted via extracellular vesicles and can be internalized through clathrin-dependent endocytosis, with secretion sensitive to autophagy inhibition 2. LRP10 overexpression induces monomeric α-synuclein secretion and modulates intracellular α-synuclein levels 2. Loss-of-function variants in LRP10 are associated with autosomal-dominant Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies 12, with LRP10 accumulating in mature Lewy bodies in affected patients 1. Pathogenic variants likely exert effects through cell non-autonomous mechanisms via astrocyte dysfunction and disturbed vesicle trafficking 1. Beyond neurodegeneration, LRP10 functions as a negative regulator of CD8 T-cell homeostasis by suppressing IL7 receptor levels, influencing tumor immunity 3.